WO2018035951A1 - 一类喹啉类新化合物 - Google Patents

一类喹啉类新化合物 Download PDF

Info

Publication number
WO2018035951A1
WO2018035951A1 PCT/CN2016/102438 CN2016102438W WO2018035951A1 WO 2018035951 A1 WO2018035951 A1 WO 2018035951A1 CN 2016102438 W CN2016102438 W CN 2016102438W WO 2018035951 A1 WO2018035951 A1 WO 2018035951A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
phenyl
amide
methoxy
quinoline
Prior art date
Application number
PCT/CN2016/102438
Other languages
English (en)
French (fr)
Inventor
许军
彭红
张文燕
陶琳
张晓丽
赵岩
赵银鹰
王晓霞
李永华
邹阳
Original Assignee
南昌弘益药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南昌弘益药业有限公司 filed Critical 南昌弘益药业有限公司
Publication of WO2018035951A1 publication Critical patent/WO2018035951A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Definitions

  • the present invention relates to a novel class of quinoline compounds, including pharmaceutically acceptable salts, prodrugs, metabolites, isotopic derivatives and solvates thereof, which are useful for modulating protein kinase activity to modulate cellular activity such as signal transduction. , proliferation and secretion of cytokines. Furthermore, the present invention relates to a pharmaceutical composition comprising the compound, which can be used for preventing or treating a protein tyrosine kinase receptor, particularly a disease associated with c-Met, VEGF, etc., and can be applied in medicine, pharmacy, biology, physiology. , biochemistry and other experiments.
  • vascular endothelial growth factor receptor VEGFR is activated during many cancer developments leading to angiogenesis.
  • Vascular endothelial growth factor-A VEGF-A
  • VEGF-A vascular endothelial growth factor-A
  • VEGFR-1 and VERFR-2 vascular endothelial growth factor receptors
  • Vascular endothelial growth factor receptors further activate downstream signaling pathways in the network, including the phosphatidylinositol-3-kinase/protein kinase B signaling pathway.
  • Immunohistochemistry experiments showed that VEGF and VEGFR were over-expressed in tumor patients, suggesting that vascular endothelial growth factor receptor activation plays an important role in tumor growth.
  • Angiogenesis plays an important role in the growth, development, reproduction, and wound healing of the organism.
  • the growth and metastasis of the primary tumor also depends on angiogenesis.
  • New tumors require more blood vessels to meet their metabolic and proliferation needs.
  • the blood circulation spreads to other tissues and organs.
  • Angiogenesis is a key factor in tumor growth, providing not only nutrition and oxygen to the tumor, but also the pathway through which tumor cells enter the system's circulation and metastasis.
  • a variety of angiogenic factors secreted by tumor cells are interconnected and regulated.
  • vascular endothelial growth factor VEGF
  • VEGF receplor, VEGFR vascular endothelial growth factor receptor
  • One of it Binding to the corresponding vascular endothelial growth factor receptor (VEGF receplor, VEGFR) stimulates the proliferation and migration of endothelial cells through specific signal transduction pathways, thereby promoting the formation of new blood vessels.
  • VEGF also known as vascular permeability factor
  • Ferrarra was a kind of glycoprotein isolated and purified from bovine pituitary follicular stellate cell culture medium.
  • a member of the Platelet derived growth factor (PDGF) family with a molecular weight of 34-45KD, is highly conserved and widely distributed in tissues such as brain, kidney, spleen, pancreas and bone in humans and animals.
  • Factor extracellular factor, hypoxia, regulation of P53 gene.
  • VEGFR binds to its ligand VEGF to produce a range of physiological and biochemical processes that ultimately promote neovascularization. In normal blood vessels, angiogenic factors and angiogenesis inhibitors maintain a relatively balanced level, and during tumor growth, high expression of VEGFR and VEGF disrupts this balance and promotes tumor angiogenesis.
  • c-Met also known as MET or HGFR, is a protein product encoded by the MET proto-oncogene (mainly present in stem cells, progenitor cells), a hepatocyte growth factor transmembrane receptor with tyrosine kinase activity.
  • c-Met is mainly expressed in epithelial cells, but also in endothelial cells, hepatocytes, nerve cells and hematopoietic cells, and plays an important role in embryo development and wound healing.
  • Hepatocyte growth factor (HGF) is the only ligand of c-Met receptor secreted by mesenchymal cells.
  • the c-Met receptor plays an important role in the cell metabolism, differentiation and signal transduction of cell apoptosis. It binds to the ligand and activates five downstream signal transduction pathways, such as RAS/RAF and phosphatidylcholine. Alcohol 3 kinase (PI3K), signal transduction and transcriptional activator (STAT), Notch and Beta-catenin promote cell mitosis, morphogenesis and other biological reactions, thereby participating in embryonic development, tissue damage repair, liver regeneration and tumor invasion. And transfer.
  • PI3K Alcohol 3 kinase
  • STAT signal transduction and transcriptional activator
  • Notch Notch
  • Beta-catenin promote cell mitosis, morphogenesis and other biological reactions, thereby participating in embryonic development, tissue damage repair, liver regeneration and tumor invasion. And transfer.
  • Hepatocyte growth factor also known as a dispersing factor, is a ligand for the tyrosine kinase variant c-Met and acts as a derivative of fibroblasts that can induce epithelial cell dispersion. Multiple epithelial cells have the effect of promoting mitosis and inducing morphological changes.
  • HGF stimulates vascular endothelial growth factor and upregulates the expression of molecules and their receptors involved in extracellular matrix proteolysis. In order to produce an effect (biological effect), HGF must bind to its receptor c-Met, the receptor tyrosine kinase.
  • the specific membrane receptor for HGF is the expression product of the proto-oncogene c-Met, which is located on chromosome 7q31 and has a size of 110 kb containing 21 exons. Its promoter domain includes many regulatory sequences such as AP1, AP2, NF2JB, and SP1.
  • HGF specifically binds to the c-Met receptor protein, induces a conformational change in the C-Met receptor protein, and activates the tyrosine protein kinase (PTK) in the receptor's intracellular protein kinase domain, which is HGF/c- The primary link of the Met signal transduction pathway.
  • PTK tyrosine protein kinase
  • the tyrosine residue of the 4-phosphorylation site near c-Met near the intracellular region undergoes autophosphorylation, followed by a series of phosphorylation reactions to activate phospholipase (PLC ⁇ ), phosphoinositide 3 Tyrosine phosphorylation of proteins such as kinase (PI3K), Ras protein, S ⁇ C protein, adaptor protein Gabl and growth factor receptor binding protein 2 (G ⁇ b2).
  • PLC ⁇ phospholipase
  • PI3K phosphoinositide 3 Tyrosine phosphorylation of proteins such as kinase (PI3K), Ras protein, S ⁇ C protein, adaptor protein Gabl and growth factor receptor binding protein 2 (G ⁇ b2).
  • HGF and c-Met regulate growth, angiogenesis, invasiveness and metastasis in many human cancers and promote tumors.
  • Activation of c-Met expression is caused by hypoxia-induced hypoxia induced by factor-1 ⁇ (HIF-1 ⁇ ) and leads to invasion of hypoxic tumors.
  • HIF-1 ⁇ reduces the expression of c-Met, which can be triggered by vascular puncture caused by VEGF inhibitors, and is selective for migration, invasive tumor cells, and propensity for metastasis through metastasis.
  • novel quinoline compounds according to the present invention are selective tyrosine protein kinase inhibitors, and their main function is to exert their effects by inhibiting tyrosine protein kinase activity.
  • the main tyrosine protein kinases inhibited by such compounds are C-met, VEGF and the like.
  • the possibility of such compounds inhibiting other disease-associated protein kinases is not excluded.
  • the present invention relates to a novel class of compounds which are tyrosine kinase inhibitors, which are of formula (I) a compound, a pharmaceutically acceptable salt, a prodrug, a metabolite, an isotope derivative and a solvate thereof, and a pharmaceutical composition comprising the same, which can be used for the prevention or treatment of treatment and control in human patients and mammalian patients , a method of delaying or preventing one or more disease states selected from diseases and conditions associated with protein tyrosine kinase receptors, particularly c-Met, VEGF, etc.; and as a protein tyrosine kinase receptor Inhibitors are used in experiments in medicine, pharmacy, biology, physiology, and biochemistry.
  • Ring A is a 3-10 membered nitrogen-containing heterocyclic ring, a 3-10 membered nitrogen-containing heterocyclic ring, a C 3-7 cycloalkyl group, a C 5-7 aromatic ring group, a C 5-7 aromatic heterocyclic group, C 7- 11 bicyclic aromatic group, C 7-11 aromatic bicyclic heteroaryl group; wherein these rings optionally substituted by one or more identical or different R 1;
  • R 1 is H, OH, NO 2 , NH 2 , CN, NO 2 , CF 3 , COOH, COOR 3 R 4 , CONR 3 , COR 3 , R 3 OH, halogen, C 1-8 alkyl; wherein C 1 -8 alkyl is optionally substituted by one or more of the same or different R 2 ;
  • R 2 is H, OH, NO 2 , NH 2 , CF 3 , COOH, halogen, C 1-8 alkyl;
  • R 3 is H, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, wherein C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl are optionally One or more identical or different R 1 substitutions; C 3-7 cycloalkyl, C 5-7 aromatic ring group, C 5-7 aromatic heterocyclic group, C 7-11 aromatic bicyclic group, C 7-11 aromatic Heterobicyclic groups wherein these rings are optionally substituted by one or more of the same or different R 2 .
  • R 4 is H, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, wherein C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl are optionally One or more identical or different R 1 substitutions; C 3-7 cycloalkyl, C 5-7 aromatic ring group, C 5-7 aromatic heterocyclic group, C 7-11 aromatic bicyclic group, C 7-11 aromatic Heterobicyclic groups wherein these rings are optionally substituted by one or more of the same or different R 2 .
  • Halogen means F, Cl, Br, I, At.
  • C 3-7 cycloalkyl refers to a cycloalkyl chain having from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of the cycloalkyl carbon can be replaced by a further defined substituent.
  • the "C 5-7 aromatic heterocyclic group” means an aromatic heterocyclic group having 5 to 7 carbon atoms, such as imidazole, thiazole, pyrazole, pyridine, pyrimidine or the like. Each hydrogen of the aromatic heterocyclic group may be replaced by a further defined substituent.
  • C 7-11 aromatic bicyclic group means an aromatic bicyclic group having 7 to 11 carbon atoms, such as naphthalene, anthracene or the like. Each hydrogen of the aromatic bicyclic group can be replaced by a further defined substituent.
  • C 7-11 aromatic heterobicyclic group means an aromatic heterobicyclic group having 7 to 11 carbon atoms, such as quinoline, isoquinoline, benzothiazole or the like. Each hydrogen of the aromatic heterobicyclic group can be replaced by a further defined substituent.
  • C l-8 alkyl means an alkyl chain having from 1 to 8 carbon atoms, for example: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, Tert-butyl.
  • Each hydrogen of the Cl-8 alkyl carbon can be replaced by a further defined substituent.
  • the "prodrug” means a derivative which is converted into a compound of the present invention by a reaction with an enzyme, a gastric acid or the like under physiological conditions in vivo, for example, by oxidation, reduction, hydrolysis or the like which is each carried out under an enzyme catalysis.
  • metabolite means a plant derived from any compound of the invention in a cell or organism, preferably a human. There are molecules.
  • Isotopic derivative means a compound which contains an isotope in an unnatural ratio to one or more of the constituent compounds. For example, hydrazine (2H or D), carbon-13 (13C), nitrogen-15 (15N), and the like.
  • Solvate means a form of the compound which is usually physically associated with a solvent by a solvolysis reaction. This physical bond involves hydrogen bonding.
  • Conventional solvents include water, ethanol, methanol, acetic acid, and the like.
  • the compound of formula (I) can be prepared in crystalline form and can be in the form of a solvate (for example, in hydrated form).
  • Suitable solvates comprise pharmaceutically acceptable solvates (e.g., hydrates), and further comprise stoichiometric solvates and non-stoichiometric solvates. In certain instances, such as when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid, the solvate will be capable of dissociating.
  • “Solvate” encompasses both solution and dissociable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
  • the invention also includes all tautomeric and stereoisomeric forms in all ratios together with mixtures thereof in any ratio, and pharmaceutically acceptable salts, prodrugs, metabolites thereof, Isotopic derivatives and solvates, and pharmaceutical compositions comprising the compounds.
  • the isomers can be separated by methods well known in the art, for example by liquid chromatography. Suitable for use by the use of, for example, the chiral stationary phase of the enantiomer.
  • the enantiomers can be separated by conversion to the diastereomers, i.e., coupled to the enantiomerically pure auxiliary compound, followed by isolation of the resulting diastereomer and cleavage of the auxiliary residue.
  • any enantiomer of a compound of formula (I) can be obtained from stereoselective synthesis using optically pure starting materials.
  • the compound of formula (I) may exist in crystalline or amorphous form. Furthermore, certain crystalline forms of the compounds of formula (I) may exist in polymorphic form and are included within the scope of the invention.
  • Many conventional analytical techniques can be used including, but not limited to, single crystal X-ray powder diffraction (XRPD) patterns, infrared (IR) spectroscopy, Raman spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and solids.
  • XRPD single crystal X-ray powder diffraction
  • IR infrared
  • Raman spectroscopy Raman spectroscopy
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • solidssNMR Nuclear magnetic resonance
  • a pharmaceutically acceptable salt of a compound of formula (I), comprising one or more basic or acidic groups comprising one or more basic or acidic groups
  • the invention also includes the corresponding pharmaceutically or toxicologically acceptable salts thereof, especially the pharmaceutically acceptable salts thereof.
  • compounds of the formula (I) which comprise an acidic group can be used according to the invention, for example as an alkali metal salt, an alkaline earth metal salt or as an ammonium salt. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as ethylamine, ethanolamine, triethanolamine or amino acids.
  • the compounds of the formula (I) which comprise one or more basic groups, ie groups which can be protonated, can be used in the form of their addition salts with inorganic or organic acids according to the invention.
  • suitable acids include hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, lactic acid, malic acid, maleic acid, benzoic acid, tartaric acid, oxalic acid, p-toluenesulfonic acid, and the like, as well as other acids known to those skilled in the art.
  • the compound of the formula (I) contains both acidic and basic groups in the molecule, the invention also includes internal salts or betaines (zwitterions) in addition to the salt forms mentioned.
  • the individual salts of formula (I) can be obtained by conventional methods known to those skilled in the art, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. obtain.
  • the invention also includes all salts of the compounds of formula (I) which are not directly suitable for use in medicine due to their low physiological compatibility, but which may, for example, be used as intermediates in chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • the term "pharmaceutically acceptable” means that the corresponding compound, carrier or molecule is suitable for administration to a human.
  • the term refers to a mammalian preferred person certified by a regulatory agency such as CFDA (China), EMEA (Europe), FDA (United States), and the like.
  • “Pharmaceutical composition” when used as a medicament, a salt, an isotopic derivative, a metabolite, a prodrug, a solvate of the compound of the formula (I) and a compound of the formula (I) of the present invention and having biological activity and or no biological activity
  • a composition of a composition of matter as a JAK inhibitor for use in the treatment or prevention of an immune, autoimmune or allergic condition, a proliferative or proliferative disease, inflammation, an allergic condition, transplant rejection, immune mediated.
  • compositions of the present invention may contain one or more pharmaceutically acceptable carriers for use as pharmaceutical formulations and pharmaceutical dosage forms for administration by injection and non-injection.
  • the carrier includes all pharmaceutical preparations in the pharmaceutical field that can be used to make injection and non-injectable routes of administration, such as diluents, Wetting agents, fillers, binders, slip agents, disintegrants, absorption enhancers, surfactants, retarders, adsorbents, suspending agents, flocculants, deflocculants, emulsifiers, common substrates , solubilizer, cosolvent, latent solvent, preservative, flavoring agent, coloring agent, antioxidant, buffer, bacteriostatic agent, isotonicity regulator, pH regulator, metal ion complexing agent, hardener, increase Thickener, absorption enhancer, etc.
  • the compounds of the formula (I) and pharmaceutical compositions of the invention may be formulated into pharmaceutical preparations and pharmaceutical dosage forms for administration by injection or non-injection. Suitable for subcutaneous injection, intramuscular injection, intravenous injection, oral administration, pulmonary (nasal or oral inhalation), rectal, topical, parenteral, intra-articular, ocular, nasal administration, etc., although most appropriate in any given case
  • the route will depend on the nature and severity of the disease state being treated and the nature of the active ingredient. They can conveniently be presented in a single dosage form and are prepared by any methods known in the art of pharmacy.
  • the disease associated with the protein tyrosine kinase receptor in the present invention is a proliferative disease such as a solid tumor or a blood cancer.
  • the compounds of the present invention and pharmaceutically acceptable salts, prodrugs, metabolites, isotopic derivatives and solvates thereof, and pharmaceutical compositions comprising the same, for use in the prevention or treatment of protein tyrosine kinases A method of receptor-related disease.
  • the results show that the compound of the present invention (I) has a good protein tyrosine kinase receptor activity and no cytotoxicity.
  • Example 1 cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinoline-4-oxy] -phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 5 ⁇ 4-[4-(2-Fluoro-4- ⁇ [1-(4-fluoro-phenyl)formyl)-cyclopropanecarbonyl chloride]-amino ⁇ -phenoxy)-6- Methoxy-quinoline-7-oxy]-piperidin-1-yl ⁇ -acetic acid
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 7 cyclopropane-1,1-dicarboxylic acid ⁇ 4-[7-(1-acetyl-piperidin-4-ylmethoxy)-6-methoxy-quinoline-4-oxyl ]-3-fluoro-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 8 cyclopropane-1,1-dicarboxylic acid ⁇ 4-[7-(5-ethyl-2hydro-pyrrol-3-ylmethoxy)-6-methoxy-quinoline-4- Oxy]-3-fluoro-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 9 ⁇ 4-[4-(2-Fluoro-4- ⁇ [1-(4-fluoro-phenyl)formyl)-cyclopropanecarbonyl chloride]-amino ⁇ -phenoxy)-6- Methoxy-quinoline-7-oxymethyl]-piperidin-1-yl ⁇ -acetic acid
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 10 cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[6-methoxy-7-(1-methylacetamide-piperidin-4-ylmethoxy)-quin Phenyl-4-oxy]-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 11 cyclopropane-1,1-dicarboxylic acid ⁇ 4-[7-(6-ethyl-pyridin-3-ylmethoxy)-6-methoxy-quinoline-4-oxy] -3-fluoro-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 12 cyclopropane-1,1-dicarboxylic acid [4-(7-cyclohexylmethoxy-6-methoxy-quinoline-4-oxo)-3-fluoro-phenyl]-amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 13 cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[7-(4-fluoro-benzyloxy)-6-methoxy-quinoline-4-oxy]-benzene Amide--amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 14 Cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[6-methoxy-7-(4-hydro-pyrazol-3-ylmethoxy)-quinoline-4- Oxy]-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 15 Cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[7-(2-fluoro-pyrimidin-5-ylmethoxy)-6-methoxy-quinoline-4- Oxy]-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 16 Cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[7-(2-hydroxy-pyrimidin-5-ylmethoxy)-6-methoxy-quinoline-4- Oxy]-phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 17 cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[7-(4-hydroxy-benzyloxy)-6-methoxy-quinoline-4-yloxy]-benzene Amide--amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 18 Cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[7-(4-hydroxymethyl-benzyloxy)-6-methoxy-quinoline-4-oxy] -phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 19 cyclopropane-1,1-dicarboxylic acid ⁇ 3-fluoro-4-[6-methoxy-7-(4-methylamino-benzyloxy)-quinoline-4-oxy] -phenyl ⁇ -amide (4-fluoro-phenyl)-amide
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 1 The synthesis method is referred to in Example 1.
  • Example 21 Inhibition of tyrosine kinase activity in vitro screening assay
  • the enzyme reaction substrate PolyB 4:1 was diluted to 20 ⁇ g/ml with potassium ion-free PBS, coated with an enzyme plate at 37 ° C for 12-16 hours, and the liquid in the well was discarded; T-PBS was washed three times. 10 minutes each time; the enzyme plate was dried in an oven at 37 ° C; the test sample was added to the wells of the coated enzyme plate (the test sample was first prepared with DMSO in a stock solution of 10-2 M, and stored after dispensing.
  • Example 22 Inhibition of proliferation of human tumor cells in vitro
  • 100 ⁇ l of the compound containing 2X and paclitaxel were added to the corresponding wells of a 96-well plate, and cultured in a carbon dioxide cell incubator for 72 hours.
  • the medium was removed, 150 ⁇ l of XTT working solution (0.3 mg/ml XTT; 0.00265 mg/ml PMS) was added to each well, and placed in a carbon dioxide incubator for 2 hours, the microplate oscillator was shaken for 5 minutes, and the absorbance was read by a microplate reader at 450 nm. The inhibition rate (%) of the compound against human tumor cells was calculated, and the IC 50 value ( ⁇ M) was determined. The results are shown in Table 2.
  • Wst-8 in CCK8 can be reduced by dehydrogenase in mitochondria to form a highly water-soluble orange-yellow formazan product (formazan) in the presence of an electron coupling reagent.
  • the depth of color is directly proportional to the proliferation of cells and inversely proportional to cytotoxicity.
  • the OD value was measured at a wavelength of 450 nm using a microplate reader, indirectly reflecting the number of viable cells, and was used to determine the cytotoxicity of the compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一类喹啉类的新化合物，该化合物为式(I)化合物及其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，及包含所述化合物的药物组合物，可用于预防或治疗与蛋白酪氨酸激酶受体相关的疾病和病症；及其可作为酪氨酸激酶抑制剂在医学、药学、生物学、生理学、生化学等实验中的应用。

Description

一类喹啉类新化合物 技术领域
本发明涉及一类喹啉类的新化合物，包括其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，其可用于调节蛋白激酶活性以便调节细胞活性如信号转导、增殖和细胞因子分泌。此外，本发明涉及包含所述化合物的药物组合物，可用于预防或治疗蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等有关疾病，并可应用在医学、药学、生物学、生理学、生化学等实验中。
背景技术
血管内皮生长因子受体VEGFR在许多癌症发展过程中发生活化从而导致血管生成。血管内皮生长因子-A(VEGF-A)，作为血管生成的关键成员，通过结合VEGFR-1和VERFR-2发挥作用。血管内皮生长因子受体进一步激活网络下游信号通路，包括磷脂酰肌醇-3-激酶/蛋白激酶B信号通路。通过免疫组化实验发现VEGF和VEGFR在肿瘤患者中过度表达，提示血管内皮生长因子受体激活在肿瘤快速生长中发挥重要作用。
血管生成在生物的生长、发育、繁殖以及伤口愈口方面发挥重要作用，原发肿瘤的生长和转移亦依赖血管生成，新生的肿瘤需要更多的血管来满足自身代谢和增殖的需要，并通过血液循环向其他组织器官扩散。血管生成是肿瘤生长的关键因素，不仅为肿瘤提供营养和氧气，同时是肿瘤细胞进入系统循环和转移的通路。肿瘤细胞分泌的多种血管生成因子之间相互联系和调控。而在众多对新生血管的形成具有调控作用的因子中，血管内皮生长因子(Vascular endothelial growth factor，VEGF)是诱导血管生成的主要因素之一，是作用最强、专属性最高的正性调控因子之一，它 与相应的血管内皮生长因子受体(VEGF receplor,VEGFR)结合后，通过特定的信号转导途径刺激内皮细胞的增殖和迁移，从而促进新生血管的形成。
VEGF也称血管渗透因子，是一类功能强大且可以产生多样生物学功能的细胞因子，于1989年由Ferrarra在牛垂体滤泡星状细胞培养液中分离纯化出来的一类糖蛋白，是血小板衍生生长因子(Platelet derived growth factor,PDGF)家族的一个成员，分子量为34～45KD，序列高度保守，广泛分布于人和动物体内的大脑、肾脏、脾脏、胰腺和骨骼等组织中，表达受细胞因子、细胞外因子、缺氧、P53基因的调节。VEGFR与其配体VEGF结合产生一系列生理和生化过程，最终促进新生血管生成。在正常血管中，血管生成因子和血管生成抑制因子保持着比较平衡的水平，而在肿瘤的生长过程中，VEGFR和VEGF的高表达破坏了这种平衡，促进了肿瘤新生血管的形成。
c-Met，又称MET或HGFR，是一种由MET原癌基因(主要存在于干细胞、祖细胞)编码的蛋白产物，是肝细胞生长因子跨膜受体，具有酪氨酸激酶活性。c-Met主要表达于上皮细胞，也可见于内皮细胞、肝细胞、神经细胞及造血细胞，在胚胎发育和创伤愈合中发挥着重要作用。肝细胞生长因子(hepatocyte growth factor,HGF)是由间质细胞分泌的c-Met受体唯一配体。
c-Met受体在细胞的代谢、分化以及细胞调亡的信号转导过程中起着重要作用，其与配体结合，可激活下游5条信号转导通路，如RAS/RAF、磷脂酰肌醇3激酶(PI3K)、信号转导与转录激活子(STAT)、Notch以及Beta-catenin，促进细胞有丝分裂、形态发生等生物学反应，从而参与胚胎发育、组织损伤修复、肝再生以及肿瘤的侵袭和转移。
肝细胞生长因子(HGF)又称分散因子，是酪氨酸激酶变体c-Met的配体，并且作为一种可以诱导上皮细胞分散的成纤维细胞的衍生因子，对许 多上皮细胞均具有促有丝分裂、诱导形态发生改变的作用。此外，HGF能刺激血管内皮生长因子，还可以上调与细胞外基质蛋白水解相关的分子及其受体的表达。为了产生效应(生物效应)，HGF必须与其受体c-Met即受体酪氨酸激酶相结合。HGF的特异性膜受体是原癌基因c-Met的表达产物，基因定位于染色体7q31，大小级110kb含21个外显子。其启动域包括AP1、AP2、NF2JB、SP1等许多调控序列。
HGF与c-Met受体蛋白特异性结合后，诱导C-Met受体蛋白发生构象改变，激活受体胞内蛋白激酶结构域中的酪氨酸蛋白激酶(PTK)，这是HGF/c-Met信号转导通路的首要环节。在大部分肿瘤细胞中，c-Met靠近胞内区的4磷酸化位点的酪氨酸残基发生自身磷酸化，接着通过一系列的磷酸化反应活化磷脂酶(PLCγ)，磷酸肌醇3激酶(PI3K)，Ras蛋白，SγC蛋白，接头蛋白Gabl和生长因子受体结合蛋白2(Gγb2)等蛋白的酪氨酸磷酸化。经瀑布式的磷酸化反应，将信号逐级放大，最终转入细胞核内的转录机制，从而调节肿瘤细胞的增殖、迁移和侵袭能力。
HGF和c-Met调节在许多人类癌症和促进肿瘤的生长,血管生成,侵袭性和转移。c-Met表达激活是通过增加factor-1α(HIF-1α)缺氧诱导所致缺氧和导致缺氧肿瘤的侵袭。HIF-1α减少c-Met的表达可以由VEGF抑制剂造成血管修剪而触发,对迁徙、侵入性肿瘤细胞和通过转移倾向性扩散具有选择性。
综上所述，本发明所涉及的喹啉类新化合物是具有选择性的酪氨酸蛋白激酶抑制剂，它们的主要作用是通过抑制酪氨酸蛋白激酶活性而发挥其作用。这类化合物所抑制的主要酪氨酸蛋白激酶有C-met、VEGF等。当然，也不排除这类化合物抑制其它与疾病相关的蛋白激酶的可能性。
发明内容
本发明涉及作为酪氨酸激酶抑制剂的一类新化合物，该化合物为式(I) 化合物及其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，及包含所述化合物的药物组合物，可用于预防或治疗在人体患者、哺乳动物患者中治疗、控制、延迟或预防一种或多种选自与蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等相关的疾病和病症的疾病状态的方法；及其可作为蛋白酪氨酸激酶受体抑制剂应用在医学、药学、生物学、生理学、生化学等实验中。
一种式(I)的新化合物：
Figure PCTCN2016102438-appb-000001
包括其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，其中：
环A为3-10元含氮杂环、3-10元含氮氧杂环、C3-7环烷基、C5-7芳香环基、C5-7芳香杂环基、C7-11芳香双环基、C7-11芳香杂双环基；其中这些环上任选被一个或多个相同或不同的R1取代；
R1是H、OH、NO2、NH2、CN、NO2、CF3、COOH、COOR3R4、CONR3、COR3、R3OH、卤素、C1-8烷基；其中C1-8烷基任选被一个或多个相同或不同的R2取代；
R2是H、OH、NO2、NH2、CF3、COOH、卤素、C1-8烷基；
R3是H、C1-8烷基、C2-8烯基、C2-8炔基，其中C1-8烷基、C2-8烯基、C2-8炔基任选被一个或多个相同或不同的R1取代；C3-7环烷基、C5-7芳香环基、C5-7芳 香杂环基、C7-11芳香双环基、C7-11芳香杂双环基，其中这些环上任选被一个或多个相同或不同的R2取代。
R4是H、C1-8烷基、C2-8烯基、C2-8炔基，其中C1-8烷基、C2-8烯基、C2-8炔基任选被一个或多个相同或不同的R1取代；C3-7环烷基、C5-7芳香环基、C5-7芳香杂环基、C7-11芳香双环基、C7-11芳香杂双环基，其中这些环上任选被一个或多个相同或不同的R2取代。
本发明的含义内，如下使用术语：
“卤素”是指F、Cl、Br、I、At。
“C3-7环烷基”是指具有3-7个碳原子的环烷基链，例如环丙基、环丁基、环戊基、环己基、环己烯基、环庚基。环烷基碳的每个氢可被进一步规定的取代基替换。
“C5-7芳香杂环基”是指具有具有5-7个碳原子的芳香杂环基，例如咪唑、噻唑、吡唑、吡啶、嘧啶等。芳香杂环基的每个氢可被进一步规定的取代基替换。
“C7-11芳香双环基”是指具有具有7-11个碳原子的芳香双环基，例如萘、茚等。芳香双环基的每个氢可被进一步规定的取代基替换。
“C7-11芳香杂双环基”是指具有具有7-11个碳原子的芳香杂双环基，例如喹啉、异喹啉、苯并噻唑等。芳香杂双环基的每个氢可被进一步规定的取代基替换。
“Cl-8烷基”是指具有1-8个碳原子的烷基链，例如：甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基。Cl-8烷基碳的每个氢可被进一步规定的取代基替换。
“前药”是指通过与酶、胃酸等在生理条件下在活体内例如通过各自在酶催化下进行的氧化、还原、水解等反应转化为本发明化合物的衍生物。
“代谢物”是指在细胞或有机体优选人中源自本发明任意化合物的所 有分子。
“同位素衍生物”是指与构成化合物之一或多个原子处以非天然比例含有同位素的所述的化合物。例如氘(2H或D)、碳-13(13C)、氮-15(15N)等。
“溶剂合物”是指通常通过溶剂分解反应与溶剂物理结合的化合物形式。此物理结合包含氢键结合。常规溶剂包含水、乙醇、甲醇、乙酸等。式(I)化合物可以结晶形式制备且可呈溶剂合物形式(例如水合形式)。适宜溶剂合物包含药学可接受的溶剂合物(例如水合物)，且进一步包含化学计量溶剂合物及非化学计量溶剂合物。在某些情形下，例如当一个或多个溶剂分子纳入结晶固体的晶格中时，溶剂合物将能够解离。“溶剂合物”涵盖溶液相及可解离溶剂合物。代表性溶剂合物包含水合物、乙醇合物及甲醇合物等。
对于式(I)化合物，本发明还包括所有比例的所有互变异构体和立体异构体形式及一起以任意比例作为其混合物，及其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，及包含所述化合物的药物组合物。
对于式(I)的化合物可通过本领域公知的方法例如通过液相色谱分离异构体。适用于通过使用例如手性固定相的对映异构体。另外，对映异构体可通过将其转化为非对映异构体来分离，即与对映异构体纯的辅助化合物偶联，随后分离所得非对异构体并裂解辅助残基。或者，可使用光学纯的起始材料从立体选择性合成获得式(I)化合物的任意对映异构体。
式(I)化合物可以晶体或无定形形式存在。此外，式(I)化合物的某些晶体形式可以多晶型形式存在，其包括在本发明范围内。可以使用许多常规分析技术包括但不限于单晶X-射线粉末衍射(XRPD)图、红外(IR)光谱、拉曼光谱、差示扫描量热法(DSC)、热重分析(TGA)和固体核磁共振(ssNMR)表征来区分式(I)化合物的多晶型。
式(I)化合物的药学可接受的盐，包含一个或多个碱性或酸性基团，本 发明还包括其相应的药学上或毒理学上可接受的盐，特别是其药学上可利用的盐。因此，包含酸性基团的式(I)化合物能根据本发明使用，例如作为碱金属盐、碱土金属盐或作为铵盐。这样的盐的更精确的实例包括钠盐、钾盐、钙盐、镁盐或与氨或有机胺如乙胺、乙醇胺、三乙醇胺或氨基酸的盐。可存在并可根据本发明以其与无机酸或有机酸的加成盐的形式使用包含一个或多个碱性基团，即能被质子化的基团的式(I)化合物。适当酸的实例包括盐酸、硫酸、磷酸、硝酸、甲磺酸、乳酸、苹果酸、马来酸、苯甲酸、酒石酸、草酸、对甲苯磺酸等以及本领域技术人员已知的其他酸。如果式(I)化合物在分子内同时包含酸性和碱性基团，本发明还包括除了提及的盐形式之外的内盐或内铵盐(两性离子)。式(I)的各个盐能由本领域技术人员已知的常规方法获得，例如通过使这些与有机或无机酸或碱在溶剂或分散剂中接触获得，或通过与其他盐进行阴离子交换或阳离子交换获得。本发明还包括式(I)化合物的所有盐，其由于低生理学相容性不直接适用于药物，但是其可例如用作化学反应的中间体或用于制备药学上可接受的盐。
在本发明中，术语“药学上可接受的”是指相应的化合物、载体或分子适于给予人。优选地，该术语是指由管理机构例如CFDA(中国)、EMEA(欧洲)、FDA(美国)等任意国家管理机构认证的用于哺乳动物优选人。
“药物组合物”在用作药物时，本发明式(I)化合物及式(I)化合物的盐、同位素衍生物、代谢物、前药、溶剂合物与具有生物活性和或不具有生物活性物质组成的组合物作为JAK抑制剂在治疗或预防免疫、自身免疫性或变应性病症、增生疾病或增殖性疾病、炎症、过敏病症、移植排斥、免疫介导中的应用。
本发明的药物组合物可以含有一种或多种药学上可接受的载体，可用作制成注射和非注射给药途径的药物制剂和药物剂型。所述载体包括药学领域所有的可用于制成注射和非注射给药途径的药物制剂，例如稀释剂、 润湿剂、填充剂、粘合剂、湿滑剂、崩解剂、吸收促进剂、表面活性剂、阻滞剂、吸附剂、助悬剂、絮凝剂、反絮凝剂、乳化剂、常用基质、增溶剂、助溶剂、潜溶剂、防腐剂、矫味剂、着色剂、抗氧剂、缓冲剂、抑菌剂、等渗调节剂、PH调节剂、金属离子络合剂、硬化剂、增稠剂、吸收促进剂等。
本发明式(I)化合物和药物组合物可制成注射或非注射给药途径的药物制剂和药物剂型。适于皮下注射、肌肉注射、静脉注射、口服、肺部(鼻或口腔吸入)、直肠、局部、肠胃外、关节内、眼部、鼻腔给药等，虽然在任意给定情况下最适当的途径将依赖于要治疗的疾病状态的性质和严重程度以及活性成分性质。它们可以方便地存在于单一剂型中，并且由药学领域公知的任意方法制备。
本发明中与蛋白酪氨酸激酶受体相关的疾病为增殖性疾病如实体瘤或血癌等。
因此，本发明的化合物及其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，及包含所述化合物的药物组合物，用于预防或治疗与蛋白酪氨酸激酶受体相关的疾病的方法。
本发明有益的效果
通过本发明技术方案的实施，结果表明本发明所述的化合物式(I)具有良好的抑制蛋白酪氨酸激酶受体活性，无细胞毒性。
具体实施方式
实施例1：环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000002
合成路线：
Figure PCTCN2016102438-appb-000003
合成方法：
取一定量的2-甲氧基-5-硝基苯酚和一定量的无水碳酸钾加入三颈瓶中，再加入N，N-二甲基甲酰胺，磁力搅拌下缓慢滴加一定量的4-溴甲基派啶，将体系升温至40℃反应过夜，倒入冰水中，析出大量固体，抽滤，滤饼用碱水洗至滤液不发黄为止，晾干，得4-(2-甲氧基-5-硝基-苯氧基甲基)-哌啶，产率70-80％；
取一定量的4-(2-甲氧基-5-硝基-苯氧基甲基)-哌啶，铁粉，氯化铵，乙醇和水加入置三颈瓶中，氮气保护下，回流反应，趁热过滤，滤液减压浓缩，加水、乙酸乙酯萃取，无水硫酸钠干燥浓缩得4-甲氧基-3-(哌啶-4-基甲氧基)-苯胺，产率70-80％；
取一定量的4-甲氧基-3-(哌啶-4-甲氧基)-苯胺、5-(甲氧基亚氧基)-2，2-二甲基-1，3-二噁烷-4，6-二酮和异丙醇置反应瓶中，加热回流反应，冷却，过滤，得5-{[4-甲氧基-3-(派啶-4-基甲氧基)-苯胺]-亚甲基}-2,2-二甲基-[1,3]二氧六环-4,6-二酮，产率50-60％；
取一定量的5-{[4-甲氧基-3-(派啶-4-基甲氧基)-苯胺]-亚甲基}-2,2-二甲基-[1,3]二氧六环-4,6-二酮、联苯、二苯醚置反应瓶中，加热反应，反应完毕后将体系降温，加入乙醚，有大量固体析出，得6-甲氧基-7-(4-哌啶－基甲氧基)喹啉-4-醇，产率70-80％；
取一定量的6-甲氧基-7-(4-哌啶－基甲氧基)喹啉-4-醇、三氯氧磷置反应瓶中，加热回流，减压旋干，用无水硫酸钠干燥得4-氯-6-甲氧基-7-(4-哌啶－基甲氧基)-喹啉，产率75-85％；
取一定量的4-氯-6-甲氧基-7-(4-哌啶－基－甲氧基)-喹啉、4-氨基-2-氟-苯酚、二苯醚置反应瓶中，加热反应，反应完毕后冷却至室温，过滤，得3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯胺，产率80-90％；
取一定量的3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯胺、环丙烷-1，1-二甲酰氯、四氢呋喃置反应瓶中，反应，旋干，得1-{3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基氨基甲酰基}-环丙烷甲酰氯，产率70-80％；
1-{3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基氨基甲酰基}-环丙烷甲酰氯、4-氟-苯胺置反应瓶中，反应，旋干，得环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺，产率75-85％。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ2.00(1H),δ1.46(2H),δ2.74(2H),δ2.0(1-NH),δ1.46(2H),δ2.74(2H),δ2.0(1-NH),δ2.74(2H),δ1.46(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H)
实施例2：环丙烷-1,1-二羧酸(3-氟-4-{6-甲氧基-7-[4-(2-氧-2-苯基-乙基)-环己基甲氧基]-喹啉-4-氧基}-苯基)-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000004
合成方法:
Figure PCTCN2016102438-appb-000005
合成方法：
取一定量的7-溴-4，6-二甲氧基-喹啉、2-(4-硝基-环己基)-1-苯乙酮、乙醇、氯化铵、水置反应瓶中，氮气保护下反应，过滤，滤液浓缩，加乙酸乙酯萃取，旋干，得2-{4-[2-(4,6-二甲氧基-喹啉-7-基)乙基]环己-1-苯基乙酮，产率78-87％；
在氮气和冰浴条件下，将一定量的2-{4-[2-(4,6-二甲氧基-喹啉-7-基)乙基]环己-1-苯基乙酮和环丙烷-1，1-二羧酸(4-氟-苯基)-酰胺(3-氟-苯基)-酰胺置反应瓶中，加四氢呋喃溶解，常温反应，旋干，加水、乙酸乙酯萃取，用无水硫酸钠干燥，浓缩，得环丙烷-1,1-二羧酸(3-氟-4-{6-甲氧基-7-[4-(2-氧-2-苯基-乙基)-环己基甲氧基]-喹啉-4-氧基}-苯基)-酰胺(4-氟-苯基)-酰胺，产率75-86％。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ1.94(1H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ1.40(2H),δ1.40(2H),δ2.51(2H),δ7.89(1H),δ7.34(1H),δ7.44(1H),δ7.34(1H),δ7.89(1H)
实施例3：环丙烷-1,1-二羧酸{4-[7-(环戊二烯-1,3-二烯基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000006
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ4.61(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ6.50(1H),δ6.40(1H),δ2.90(2H),δ6.49(1H)
实施例4：环丙烷-1,1-二羧酸{3-氟-4-[7-(3-羟基-环戊二烯-1,3-二烯基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000007
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ4.61(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ6.40(1H),δ2.90(2H),δ15.0(1-OH),δ6.5(1H)
实施例5：{4-[4-(2-氟-4-{[1-(4-氟-苯基氨酸甲酰基)-环丙烷甲酰氯]-氨基}-苯氧基)-6-甲氧基-喹啉-7-氧基]-哌啶-1-基}-乙酸
化合物结构：
Figure PCTCN2016102438-appb-000008
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ2.00(1H),δ1.46(2H),δ2.42(2H),δ2.42(2H),δ1.46(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ3.30(2H),δ11.0(1-OH)
实施例6：环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(吡啶-3-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000009
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.90(1H),δ7.42(1H),δ8.55(1H),δ8.70(1H)
实施例7：环丙烷-1,1-二羧酸{4-[7-(1-乙酰基-哌啶-4-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000010
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ2.00(1H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ1.46(2H),δ3.34(2H),δ3.34(2H),δ1.46(2H),δ2.02(3H)
实施例8：环丙烷-1,1-二羧酸{4-[7-(5-乙基-2氢-吡咯-3-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000011
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ4.61(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.96(1H),δ6.96(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ2.0(2H),δ1.4(2H),δ0.9(3H),δ5.0(1H)
实施例9：{4-[4-(2-氟-4-{[1-(4-氟-苯基氨酸甲酰基)-环丙烷甲酰氯]-氨基}-苯氧基)-6-甲氧基-喹啉-7-氧基甲基]-哌啶-1-基}-乙酸
化合物结构：
Figure PCTCN2016102438-appb-000012
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ2.00(1H),δ1.46(2H),δ2.24(2H),δ2.24(2H),δ1.46(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ3.30(2H),δ11.0(1-OH)
实施例10：环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(1-甲基乙酰胺-哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000013
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ2.00(1H),δ1.46(2H),δ2.24(2H),δ2.24(2H),δ1.46(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ3.25(2H),δ8.0(1-NH),δ3.71(3H)
实施例11：环丙烷-1,1-二羧酸{4-[7-(6-乙基-吡啶-3-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000014
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.82(1H),δ7.33(1H),δ8.73(1H),δ2.92(2H),δ1.24(3H)
实施例12：环丙烷-1,1-二羧酸[4-(7-环己基甲氧基-6-甲氧基-喹啉-4-氧基)-3-氟-苯基]-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000015
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ3.90(2H),δ1.94(1H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ1.40(2H),δ1.44(2H),δ1.44(2H),δ1.40(2H)
实施例13：环丙烷-1,1-二羧酸{3-氟-4-[7-(4-氟-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000016
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.17(1H),δ6.90(1H),δ6.90(1H),δ7.17(1H)
实施例14：环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(4氢-吡唑-3-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000017
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ4.0(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.5(1H),δ1.4(2H)
实施例15：环丙烷-1,1-二羧酸{3-氟-4-[7-(2-氟-嘧啶-5-基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000018
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ8.7(1H),δ8.7(1H)
实施例16：环丙烷-1,1-二羧酸{3-氟-4-[7-(2-羟基-嘧啶-5-基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000019
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ8.12(1H),δ8.12(1H),δ5.0(1H)
实施例17：环丙烷-1,1-二羧酸{3-氟-4-[7-(4-羟基-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000020
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.02(1H),δ6.66(1H),δ6.66(1H),δ7.02(1H),δ5.0(1-OH)
实施例18：环丙烷-1,1-二羧酸{3-氟-4-[7-(4-羟甲基-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000021
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.12(1H),δ7.12(1H),δ7.12(1H),δ4.79(2H),δ2.0(1-OH)
实施例19：环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(4-甲胺基-苄氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000022
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ6.97(1H),δ6.36(1H),δ6.97(1H),δ4.0(1-NH),δ2.78(3H)
实施例20：环丙烷-1,1-二羧酸(3-氟-4-{7-[3-(2-氟-乙基)-苄氧基]-6-甲氧基-喹啉-4-氧基}-苯基)-酰胺(4-氟-苯基)-酰胺
化合物结构：
Figure PCTCN2016102438-appb-000023
合成方法参照实施例1。
1H-NMR(400MHZ,CDCl3,TMS,ppm):
δ7.29(1H),δ7.32(1H),δ8.55(1H),δ6.47(1H),δ3.73(3H),δ5.20(2H),δ6.69(1H),δ7.24(1H),δ7.18(1H),δ8.0(1-NH),δ8.0(1-NH),δ7.62(1H),δ6.95(1H),δ6.95(1H),δ7.62(1H),δ0.90(2H),δ0.90(2H),δ7.05(1H),δ7.05(1H),δ7.14(1H),δ7.01(1H),δ2.75(2H),δ4.42(2H)
实施例21：酪氨酸激酶活性抑制体外筛选试验
研究化合物对酪氨酸激酶活性抑制，用IC50表示。
实验方法：酶反应底物PolyB4：1用无钾离子的PBS稀释成20μg/ml，包被酶标板置37℃反应12-16小时，弃去孔中液体；T-PBS洗板三次，每次10分钟；于37℃烘箱中干燥酶标板；在包被好酶标板孔内加入受试样品(受 试样品先用DMSO配制成10-2M的储备液，分装后存放于-20℃，临用前用反应液缓冲液稀释到所需浓度，加至实验孔内，使其在100μl反应体系中达到相应的终浓度)；加入ATP和受试酪氨酸激酶(加入用反应缓冲液稀释的ATP溶液，加入用反应缓冲液稀释的受试酪氨酸激酶)；将反应体系置于湿盒内，37℃摇床避光反应1小时，反应结束后T-PBS洗板三次；加入抗体，37℃摇床反应30分钟，T-PBS洗板三次；加入辣根过氧化物酶标记的羊抗鼠，37℃摇床反应30分钟，T-PBS洗板三次；加入OPD显色液，室温避光反应1-10分钟；加入2M HB2SOB4 50μl中止反应，用可调波长式微孔板酶标仪测AB490值。
表1 对酪氨酸激酶活性抑制IC50(nM)
Figure PCTCN2016102438-appb-000024
注：1.(A)20nM或更小；
2.(B)>20nM至100nM；
3.(C)>100nM
实施例22：对人肿瘤细胞体外增殖的抑制作用
取人胃癌细胞SNU-5、肝癌细胞Hep-G2、肺癌细胞EBC-1、胃癌细胞BGC-823、脑星形胶质母细胞瘤U87MG、宫颈癌细胞Hela、乳腺癌细胞Bcap-37，将化合物用DMSO配制成20mM的溶液，将系列化合物和紫杉醇(储液0.2mM)用DMSO 3倍梯度稀释(10个浓度)；分别取5μl梯度稀释好的化合物溶液和紫杉醇加入到495μl含有10％FBS的培养基中，配制成2X待测化合物。
取100μl含2X待测化合物、紫杉醇加到96孔板相应孔中，二氧化碳细胞培养箱培养72小时。
去除培养基，每孔加入XTT工作液(0.3mg/ml XTT；0.00265mg/ml PMS)150μl，二氧化碳培养箱中放置2小时，微孔板振荡器震荡5分钟，酶标仪450nm读取吸光值，计算化合物对人肿瘤细胞的抑制率(％)，求得IC50值(μM)。结果见表2。
表2 对人肿瘤细胞体外增殖的抑制作用(IC50，μM)
化合物 SNU-S EBC-1 BGC-823 HepG2 U87-MG Hele Bcap-37
本发明实施例1化合物 1.025 1.253 1.011 0.985 1.085 0.842 0.996
本发明实施例2化合物 1.004 1.354 1.113 1.098 0.912 1.056 0.846
本发明实施例3化合物 0.821 1.332 0.975 1.348 1.051 0.904 1.312
本发明实施例4化合物 1.125 1.078 0.934 1.412 1.099 0.842 1.175
本发明实施例5化合物 0.961 1.112 0.894 1.231 1.107 1.006 0.947
本发明实施例6化合物 1.031 0.941 1.372 1.254 1.009 0.812 0.961
本发明实施例7化合物 0.913 1.243 1.192 0.987 1.351 1.018 0.905
本发明实施例8化合物 0.924 1.054 1.287 0.966 1.147 1.042 1.379
本发明实施例9化合物 1.224 1.021 1.181 1.348 1.541 1.073 1.542
本发明实施例10化合物 1.173 1.004 1.243 1.116 1.384 0.991 1.314
本发明实施例11化合物 0.904 1.075 1.134 1.079 0.842 0.931 0.843
本发明实施例12化合物 0.840 0.934 1.221 1.112 1.038 0.917 0.803
本发明实施例13化合物 1.402 0.804 0.981 1.383 1.075 1.134 1.039
本发明实施例14化合物 0.812 0.935 1.246 1.184 1.098 1.007 0.921
本发明实施例15化合物 0.765 1.245 1.037 1.128 1.039 1.043 0.954
本发明实施例16化合物 1.107 0.977 0.731 1.208 1.345 1.073 0.831
本发明实施例17化合物 1.008 0.873 0.982 1.368 1.118 0.943 1.006
本发明实施例18化合物 1.241 1.085 0.976 1.143 0.924 1.197 1.007
本发明实施例19化合物 1.076 1.243 1.008 0.976 1.133 1.077 1.107
本发明实施例20化合物 1.066 1.345 1.124 1.033 0.931 1.121 0.889
实施例23：细胞毒性试验
实验原理：CCK8中的wst-8在电子耦合试剂存在的情况下，可以被线粒体内的脱氢酶还原生成高度水溶性的橙黄色的甲臜产物(formazan)。颜色的深浅与细胞的增殖成正比，与细胞毒性成反比。使用酶标仪在450nm波长处测定OD值，间接反映活细胞的数量，用于测定化合物的细胞毒性。
实验方法：根据实验过程中流式细胞仪及显微镜的形态观察，各化合物毒性非常小。为了进一步定量确认化合物毒性，用CCK-8的方法检测了HELA细胞的增殖，详细方法如下：将化合物按照10个不同浓度用DMSO稀释，取100ml稀释后的化合物加入96孔板；将HELA细胞调整到2×105/ml，取100ml细胞加入到上述已经加入化合物的96孔板中，混匀后，37℃细胞培养箱孵育24小时；向每孔加入20μl CCK溶液；将培养板在培养箱内孵育4小时；用酶标仪测定在450nm处的吸光度。
实验结果：各化合物均没有浓度依赖性地改变细胞数量，表明这些化合物对HELA细胞无毒性。结果见表3。
表3 细胞毒性实验结果
化合物 细胞毒性
本发明实施例1化合物 无
本发明实施例2化合物 无
本发明实施例3化合物 无
本发明实施例4化合物 无
本发明实施例5化合物 无
本发明实施例6化合物 无
本发明实施例7化合物 无
本发明实施例8化合物 无
本发明实施例9化合物 无
本发明实施例10化合物 无
本发明实施例11化合物 无
本发明实施例12化合物 无
本发明实施例13化合物 无
本发明实施例14化合物 无
本发明实施例15化合物 无
本发明实施例16化合物 无
本发明实施例17化合物 无
本发明实施例18化合物 无
本发明实施例19化合物 无
本发明实施例20化合物 无
以上所述仅是本发明的优选实施方式，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (11)

  1. 一种式(I)的新化合物：
    Figure PCTCN2016102438-appb-100001
    包括其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物，其中：
    环A为3-10元含氮杂环、3-10元含氮氧杂环、C3-7环烷基、C5-7芳香环基、C5-7芳香杂环基、C7-11芳香双环基、C7-11芳香杂双环基；其中这些环上任选被一个或多个相同或不同的R1取代；
    R1是H、OH、NO2、NH2、CN、NO2、CF3、COOH、COOR3R4、CONR3、COR3、R3OH、卤素、C1-8烷基；其中C1-8烷基任选被一个或多个相同或不同的R2取代；
    R2是H、OH、NO2、NH2、CF3、COOH、卤素、C1-8烷基；
    R3是H、C1-8烷基、C2-8烯基、C2-8炔基，其中C1-8烷基、C2-8烯基、C2-8炔基任选被一个或多个相同或不同的R1取代；C3-7环烷基、C5-7芳香环基、C5-7芳香杂环基、C7-11芳香双环基、C7-11芳香杂双环基，其中这些环上任选被一个或多个相同或不同的R2取代；
    R4是H、C1-8烷基、C2-8烯基、C2-8炔基，其中C1-8烷基、C2-8烯基、C2-8炔基任选被一个或多个相同或不同的R1取代；C3-7环烷基、C5-7芳香环基、C5-7芳香杂环基、C7-11芳香双环基、C7-11芳香杂双环基，其中这些环上任选被一个 或多个相同或不同的R2取代。
  2. 如权利要求1所述的化合物，其中式(I)所述化合物选自：
    环丙烷-1,1-二羧酸(3-氟-4-{6-甲氧基-7-[4-(2-氧-2-苯基-乙基)-环己基甲氧基]-喹啉-4-氧基}-苯基)-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{4-[7-(环戊二烯-1,3-二烯基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(3-羟基-环戊二烯-1,3-二烯基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    {4-[4-(2-氟-4-{[1-(4-氟-苯基氨酸甲酰基)-环丙烷甲酰氯]-氨基}-苯氧基)-6-甲氧基-喹啉-7-氧基]-哌啶-1-基}-乙酸
    环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(吡啶-3-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{4-[7-(1-乙酰基-哌啶-4-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{4-[7-(5-乙基-2氢-吡咯-3-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
    {4-[4-(2-氟-4-{[1-(4-氟-苯基氨酸甲酰基)-环丙烷甲酰氯]-氨基}-苯氧基)-6-甲氧基-喹啉-7-氧基甲基]-哌啶-1-基}-乙酸
    环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(1-甲基乙酰胺-哌啶-4-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{4-[7-(6-乙基-吡啶-3-基甲氧基)-6-甲氧基-喹啉-4-氧基]-3-氟-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸[4-(7-环己基甲氧基-6-甲氧基-喹啉-4-氧 基)-3-氟-苯基]-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(4-氟-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(4氢-吡唑-3-基甲氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(2-氟-嘧啶-5-基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(2-羟基-嘧啶-5-基甲氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(4-羟基-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[7-(4-羟甲基-苄氧基)-6-甲氧基-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸{3-氟-4-[6-甲氧基-7-(4-甲胺基-苄氧基)-喹啉-4-氧基]-苯基}-酰胺(4-氟-苯基)-酰胺
    环丙烷-1,1-二羧酸(3-氟-4-{7-[3-(2-氟-乙基)-苄氧基]-6-甲氧基-喹啉-4-氧基}-苯基)-酰胺(4-氟-苯基)-酰胺
  3. 如权利要求1或2所述的化合物，其是各类晶型，包括但不限于结晶、无定形及其他各类晶型。
  4. 一种药物组合物，包括权利要求1-3中任一项所述的化合物或其可药用盐、前药、代谢物、同位素衍生物和溶剂合物以及可药用载体或赋型剂，任选与一种或多种其他药物组合物结合。
  5. 如权利要求1-3中任一项所述的化合物或如权利要求4所述的药物组合物，其可制成注射或非注射给药途径的药物制剂和药物剂型。
  6. 用作药物的如权利要求1-3中任一项所述的化合物或如权利要求4 或5所述的药物组合物。
  7. 如权利要求1-3中任一项所述的化合物或如权利要求4或5所述的药物组合物，其用于在人体患者中预防或治疗与蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等有关疾病。
  8. 如权利要求6或7所述的化合物或药物组合物，其中所述与蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等有关疾病选自：为人和动物细胞增殖性相关的实体瘤或血癌。
  9. 如权利要求1-3中任一项所述的化合物或如权利要求4或5所述的药物组合物，其可作为蛋白酪氨酸激酶受体抑制剂应用在医学、药学、生物学、生理学、生化学等实验中。
  10. 一种如权利要求1-3中任一项所述的化合物或其可药用盐、前药、代谢物、同位素衍生物和溶剂合物，或如权利要求4或5所述的药物组合物用于治疗与蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等相关的疾病和病症的方法。
  11. 如权利要求10所述的方法，其中所述与蛋白酪氨酸激酶受体尤其是与c-Met、VEGF等相关的疾病和病症选自：为人和动物细胞增殖性相关的实体瘤或血癌。
PCT/CN2016/102438 2016-08-24 2016-10-18 一类喹啉类新化合物 WO2018035951A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610713451.9A CN107778285A (zh) 2016-08-24 2016-08-24 一类喹啉类新化合物
CN201610713451.9 2016-08-24

Publications (1)

Publication Number Publication Date
WO2018035951A1 true WO2018035951A1 (zh) 2018-03-01

Family

ID=61246060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/102438 WO2018035951A1 (zh) 2016-08-24 2016-10-18 一类喹啉类新化合物

Country Status (2)

Country Link
CN (1) CN107778285A (zh)
WO (1) WO2018035951A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2012171487A1 (zh) * 2011-06-17 2012-12-20 天津隆博基因药物科技有限公司 芳氧基喹啉类衍生物及其治疗用途
CN103816157A (zh) * 2012-11-16 2014-05-28 常辉 一类治疗溃疡性结肠炎的化合物及其用途
WO2014145693A1 (en) * 2013-03-15 2014-09-18 Exelixis, Inc. Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CN104817497A (zh) * 2015-03-20 2015-08-05 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012171487A1 (zh) * 2011-06-17 2012-12-20 天津隆博基因药物科技有限公司 芳氧基喹啉类衍生物及其治疗用途
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN103816157A (zh) * 2012-11-16 2014-05-28 常辉 一类治疗溃疡性结肠炎的化合物及其用途
WO2014145693A1 (en) * 2013-03-15 2014-09-18 Exelixis, Inc. Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CN104817497A (zh) * 2015-03-20 2015-08-05 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN107778285A (zh) 2018-03-09

Similar Documents

Publication Publication Date Title
DK2118074T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
CA2747417C (en) Compounds for the prevention and treatment of cardiovascular disease
CN104119317B (zh) 含1,2,3-三氮唑的喹啉类化合物及其制备方法和应用
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
BR112013012488B1 (pt) Azetidinas quinazolina carboxamida, seus usos e seu processo de fabricação, composição farmacêutica, e kit
TW201418220A (zh) 新的喹啉類化合物及其用途
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
WO2017148406A1 (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
JP6916562B2 (ja) 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
JP2021165270A (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
EP2970128B1 (en) Base addition salts of nitroxoline and uses thereof
CN107151233B (zh) 含腙的嘧啶类衍生物及其用途
CA3147852C (en) Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof
CN111448193A (zh) Srpk1抑制剂
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
WO2019185033A1 (zh) 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
WO2018035950A1 (zh) 作为酪氨酸蛋白激酶抑制剂的一类化合物
CN106866642B (zh) 含芳基酰腙结构的喹唑啉类化合物及其应用
WO2018133159A1 (zh) 一类喹啉类新化合物制备方法
WO2018035951A1 (zh) 一类喹啉类新化合物
CN108948014A (zh) 1-芳基-4-氧基-1,4-二氢喹啉结构的吡啶并杂环类化合物的制备及应用
CN105017217A (zh) 含吡唑酮的喹啉类化合物及其制备方法和应用
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2013143376A1 (zh) 含1，2，4-三嗪-3，5-二酮的喹啉类化合物及其应用
WO2010083649A1 (zh) 双芳基脲类衍生物及用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16913971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16913971

Country of ref document: EP

Kind code of ref document: A1